Биохимические и молекулярно-генетические исследования парвовируса В19 при оценке безопасности препаратов альбумина и иммуноглобулина
Диссертация
Лечебные препараты альбумина и иммуноглобулина, так же как и другие препараты, получаемые из плазмы крови, могут быть потенциально опасны в отношении передачи возбудителей инфекционных заболеваний, поэтому их производство требует комплексного подхода для предотвращения контаминации патогенами конечного продукта. Несмотря на успехи, достигнутые в области повышения вирусной безопасности лечебных… Читать ещё >
Содержание
- 1. ОБЗОР ЛИТЕРАТУРЫ
- 1. 1. История открытия парвовируса В
- 1. 2. Таксономическая классификация, структура и организация генома парвовируса В
- 1. 2. 1. Таксономия представителей семейства Parvoviridae
- 1. 2. 2. Структура вириона и организация генома
- 1. 2. 3. Генетическая вариабельность парвовируса В
- 1. 3. Патогенез
- 1. 3. 1. Жизненный цикл и тропизм вируса
- 1. 3. 2. Культивирование парвовируса В
- 1. 3. 3. Цитопатология
- 1. 3. 4. Патогенез и иммунный ответ
- 1. 4. Клинические аспекты парвовирусной инфекции
- 1. 4. 1. Проявления инфекции у здоровых лиц
- 1. 4. 2. Парвовирусная инфекция у лиц с иммуннодефицитными состояниями и гематологическими заболеванями
- 1. 5. Диагностика парвовирусной инфекции
- 1. 6. Эпидемиология и трансмиссия
- 1. 7. Парвовирус В19 и безопасность препаратов крови
- 1. 7. 1. Распространенность парвовируса В19 среди доноров
- 1. 7. 2. Контаминация пулов плазмы и препаратов крови парвовирусом В
- 1. 7. 3. Основные способы получения лечебных препаратов из плазмы крови
- 1. 7. 4. Основные производственные методы инактивации/элиминации патогенов и их эффективность в отношении парвовируса В
- 2. 1. Исследуемый материал
- 2. 2. Подготовка образцов для исследования
- 2. 3. Выделение ДНК парвовируса В
- 2. 4. Выявление и количественное определение ДНК парвовируса В
- 2. 5. Получение фрагментов ДНК парвовируса В19 для секвенирования
- 2. 6. Секвенирование фрагментов ДНК парвовируса В
- 2. 7. Выведение аминокислотных последовательностей
- 2. 8. Филогенетический анализ
- 2. 9. Выявление и определение количественного содержания антител к парвовирусу В
- 2. 10. Модельное фракционирование контаминированных пулов плазмы
- 2. 11. Определение фактора вирусной редукции
- 2. 12. Статистическая обработка результатов
- 3. 1. Выявление генетических и серологических маркеров парвовируса В19 в крови доноров
- 3. 2. Определение генотипа и филогенетический анализ российских штаммов парвовируса В
- 3. 3. Оценка частоты контаминации парвовирусом В19 производственных пулов плазмы для фракционирования
- 3. 4. Исследование динамики изменения концентрации ДНК парвовируса В19 и оценка уровня вирусной редукции по стадиям технологического процесса
- 3. 5. Исследование препаратов альбумина и иммуноглобулина на содержание генетических и серологических маркеров парвовируса В
Список литературы
- Анастасиев, В. В. Иммуноглобулин для внутривенного введения / В. В. Анастасиев. Нижний Новгород: НГМА, 2000. — 168 с.
- Гланц, С. Медико-биологическая статистика / С. Гланц — под ред. Н. Е. Бузикашвили, Д. В. Самойлова — пер. с англ. Ю. А. Данилова. М.: Практика, 1998.-459 с.
- Левин, И. Служба крови и препараты плазмы: (междунар. аналит. обзор). / И. Левин, В. М. Русанов. М: Медпрактика — М, 2007. — 316 с.
- Молекулярная эпидемиология парвовирусной инфекции в Республике Беларусь / М. А. Ермолович и др. // Вопр. вирусол. 2010. — № 2. — С. 26 — 31.
- Оприщенко, С. А. Лечебные препараты крови в современной медицине / С. А. Оприщенко, В. В. Захаров, В. М. Русанов. М.: Медпрактика — М, 2011. -328 с.
- Русанов, В. М. Лечебные препараты крови / В. М. Русанов, И. Левин. М.: Медпрактика, 2004. — 284 с.
- Русанов, В. М. Фракционирование белков плазмы в производстве препаратов крови / В. М. Русанов, Л. И. Скобелев. Москва: Медицина, 1983. — 224 с.
- A genetically engineered cell line that produces empty capsid of В19 (human) parvovirus / S. Kajigaya et al. // PNAS 1989. — Vol. 86, N 19 — P. 7601 — 7605.
- A linked donor-recipient study to evaluate parvovirus В19 transmission by blood component transfusion / S. H. Kleiman et al. // Blood. 2009. — Vol. 114, N 17.-P. 3677−3683.
- A murine monoclonal IgM antibody specific for blood group P antigen (globoside) / A. E. von der Borne et al. // Br. J. Haematol. 1986. — Vol. 63, N 1. -P. 35 -46.
- A new parvovirus genotype persistent in human skin / K. Hokynar et al. // J. Virol. 2002. — Vol. 302, N 2. — P. 224 — 228.
- A putative nucleoside triphosphate-binding domain in the nonstructural protein of B19 parvovirus is required for cytotoxicity / M. Momoeda et al. // J. Virol. -1994. Vol. 68, N 12. — P. 8443 — 8446.
- A viral phospholipase A2 is required for parvovirus infectivity / Z. Zadori et al. // Dev. Cell. 2001. — Vol. 1, N 2. — P. 291 — 302.
- Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity / M. Soderlund et al. // J. Infect. Dis. 1995. — Vol. 171, N3.-P. 710 713.
- Acute encephalopathy with human parvovirus B19 infection in hereditary spherocytosis / K. Oshima et al. // Pediatr. Infect. Dis. J. 2008. — Vol. 27, N 7. -P. 651 -652.
- Acute encephalopathy with parvovirus B19 infection in sickle cell disease / S. Bakhshi et al. // Arch. Dis. Child. 2002. — Vol. 87, N 6. — P. 541 — 542.
- Advances in human B19 erythrovirus biology / A. Servant-Delmas et al. // J. Virol. 2010. — Vol. 84, N 19. — P. 9658 — 9665.
- Albumin batches and B19 parvovirus DNA / J. J. Lefrere et al. // Transfusion. 1995.-Vol. 35, N5.-P. 389−391. '
- Al-Khan, A. Parvovirus B-19 Infection During Pregnancy / A. Al-Khan, A. Caligiuri, J. Apuzzio // Infect Dis Obstet Gynecol. 2003. — Vol. 11, N 3. — P. 175 -179.
- Analysis of B19 virus contamination in plasma pools for manufacturing by using a competitive polymerase chain reaction assay / G. Gallinella et al. // Vox Sang. 2002. — Vol. 83, N 4. — P. 324 -331.
- Anderson, L. J. Role of parvovirus B19 in human disease / L. J. Anderson // Pediatr. Infect. Dis. J. 1987. — Vol. 6, N 8. — P. 711 — 718.
- Anderson, M. J. Diagnosis of human parvovirus infection by dot-blot hybridization using cloned viral DNA / M. J. Anderson, S. E. Jones, A. C. Minson // J. Med. Virol. 1985. — Vol. 15, N 2. — P. 163 — 172.
- Antibodies to parvovirus B19 NS-1 protein in infected individuals / A. von Podlotzki et al. // J. Gen. Virol. 1995. — Vol. 76, N 3. — P. 519 — 527.
- Antibodies to the nonstructural protein of parvovirus B19 in persistently infected patients: implication for pathogenesis / A. von Podlotzki et al. // J. Infect. Dis. 1995. — Vol. 172, N 5. — P. 1356 — 1359.
- Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection / P. von Landenberg et al. // Arthritis. Rheum. 2003. — Vol. 48, N 7. — P. 1939 — 1947.
- Apoptosis of liver-derived cells induced by parvovirus B19 nonstructural protein / B. D. Poole et al. // J. Virol. 2006. — Vol. 80, N 8. — P. 4114 — 4121.
- Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection / K. O. Schowengerdt et al. // Circulation. 1997. — Vol. 96, N 10.-P. 3549−3554.
- Baylis, S. A. Evaluation of different assays for the detection of parvovirus B19 DNA in human plasma / S. A. Baylis, N. Shah, P. D. Minor // J. Virol. Methods. -2004. Vol.121, N 1. — P. 7 — 16.
- Beard, C. Transient expression of B19 parvovirus gene products in COS-7 cells transfected with B19-SV40 hybrid vectors / C. Beard, J. St. Amand, C. R. Astell //Virology. 1989.-Vol. 172, N2.-P. 659−664.
- Biological and immunological relations among human parvovirus B19 genotypes 1 to 3 / A. Ekman et al. // J. Virol. 2007. — Vol. 81, N 13. — P. 6927 -6935.
- Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue / P. Norja et al. // PNAS. 2006. — Vol. 103, N 19. — P. 7450−7453.
- Block to the production of full-length B19 virus transcripts by internal polyadenylation is overcome by replication of the viral genome / W. Guan et al. // J. Virol. 2008. — Vol. 82, N 20. — P. 9951 — 9963.
- Blood donor screening for parvovirus B19 in Germany and Austria / M. Schmidt et al. // Transfusion. 2007. — Vol. 47, N 10. — P. 1775 — 1782.
- Bonsch, C. Interaction of parvovirus B19 with human erythrocytes alters virus structure and cell membrane integrity / C. Bonsch, C. Kempf, C. Ros // J. Virol. -2008.-Vol. 82, N23.-P. 11 784- 11 791.
- Breese, C. Encephalopathy with erythema infectiosum / C. Breese, F. A. Horner // Am. J. Dis. Child. 1977. — Vol. 131, N 1. — P. 65 — 67.
- Brown, K. E. Erythrocyte P antigen: cellular receptor for B19 parvovirus / K. E. Brown, S. M. Anderson, N. S. Young // Science. 1993. — Vol. 262, N 5130. — P. 114−117.
- Bruu, A. L. Evaluation of five commercial tests for detection of immunoglobulin M antibodies to human parvovirus B19 / A. L. Bruu, S. A. Nordbo // J. Clin. Microbiol. 1995. — Vol. 33, N 5. — P. 1363 — 1365.
- Caul, E. O. Intrauterine infection with human parvovirus B19: a light and electron microscopy study / E. O. Caul, M. J. Usher, P. A. Burton // J. Med. Virol. -1988. Vol. 24, N 1. — P. 55 — 66.
- Caution in evaluation of removal of virus by filtration: misinterpretation due to detection of viral genome fragments by PCR / M. Tsujikawa et al. // J. Virol. Methods.-2011.-Vol. 178, N 1 2.-P. 39−43.
- Characteristics and taxonomy of Parvoviridae / G. Siegl et al. // Intervirology.- 1985. Vol. 23, N 2. — P. 61 — 73.
- Characterization of parvovirus B19 genotype 2 in KU812Ep6 cells / J. Bliimel et al. // J. Virol. 2005. — Vol. 79, N 22. — P. 14 197 — 14 206.
- Christensen, J. A novel cellular site-specific DNA-binding protein cooperates with the viral NS1 polypeptide to initiate parvovirus DNA replication / J. Christensen, S. F. Cotmore, P. Tattersall // J. Virol. 1997. — Vol. 71, N 2. — P. 1405- 1416.
- Chronic parvovirus B19 infection induces the production of anti-virus antibody with autoantigen binding properties / C. Lunardi et al. // Eur. J. Immunol. 1998. -Vol. 28, N3.-P. 936−948.
- Clinical manifestation of human parvovirus B19 in adults / A. D. Woolf et al. // Arch. Intern. Med. 1989. — Vol. 149, N 5. — P. 1153 — 1156.
- Cloning of the human parvovirus B19 genome and structural analysis of its palindromic termini / V. Deiss et al. // Virology. 1990. — Vol. 175, N 1. — P. 247 -254.
- Cohen, B. J. Genetic variants of parvovirus B19 identified in the United Kingdom: implications for diagnostic testing / B.J. Cohen, J. Gandhi, J. P. Clewley // J. Clin. Virol. 2006. — Vol. 36, N 2. — P. 152 — 155.
- Collaborative study to establish a World Health Organization International genotype panel for parvovirus B19 DNA nucleic acid amplification technology (NAT)-based assays / S. A. Baylis et al. // Vox Sang. 2012. — Vol. 102, N 3. — P. 204−211.
- Corcoran, A. Advances in the biology, diagnosis and host-pathogen interactions of parvovirus B19 / A. Corcoran, S. Doyle // J. Med. Microbiol. 2004. -Vol. 53, N6.-P. 459−475.
- Cryo-electron microscopy studies of empty capsids of human parvovirus B19 complexed with its cellular receptor / P. R. Chipman et al. // PNAS. 1996. — Vol. 93, N 15.-P. 7502−7506.
- Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests / K. Hokynar et al. // J. Clin. Microbiol. 2004. -Vol. 42, N5.-P. 2013−2019
- Detection of an erythrovirus sequence distinct from B19 in a child with acute anemia / Q. T. Nguyen et al. // Lancet. 1998. — Vol. 352, N 9139. — P. 1524
- Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay / L. J. Anderson et al. // J. Clin. Microbiol. 1986. -Vol. 24, N4.-P. 522−526.
- Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction / F. McOmish et al. // J. Clin. Microbiol. 1993. — Vol. 31, N2.-P. 323−328.
- Different susceptibility of B19 virus and mice minute virus to low pH treatment / N. Boschetti et al. // Transfusion. 2004. — Vol. 44, N 7. — P. 1079 -1086.
- Direct demonstration of the human parvovirus in erythroid progenitor cells infected in vitro / N. Young et al. // J. Clin. Investig. 1984. — Vol. 74, N 6. — P. 2024 — 2032.
- Discovery and analysis of a novel parvovirus B19 genotype 3 isolate in the United States / L. A. Rinckel et al. // Transfusion. 2009. — Vol. 49, N 7. — P. 1488 — 1492.
- Dot blot hybridization assay of B19 virus DNA in clinical specimens / J. Mori et al. // J. Clin. Microbiol. 1989. — Vol. 27, N 3. — P. 459 — 464.
- Doyle, S. The immune response to parvovirus B19 exposure in previously seronegative and seropositive individuals / S. Doyle, A. Corcoran // J. Infect. Dis. -2006.-Vol. 194, N2.-P. 154- 158.
- Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products / M. C. Menconi et al. // Transfus. Med. -2009.-Vol. 19, N4.-P. 213−217.
- Electron microscopic estimation of removal of parvovirus B19 (HB19V) by nanofiltration with a novel filter membrane / K. Yamaguchi et al. // J. Membrane Science. 2007. — Vol. 298, N 1 — 2. — P. 99 — 109.
- Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003−2009 / K. Kooistra et al. // Vox Sang. 2011. — Vol. 100, N 3. — P. 261 -266.
- Erythroid crisis caused by parvovirus B19 transmitted via red blood cell transfusion / Y. Tsukada et al. // Intern. Med. 2011. — Vol. 50, N 20. — P. 2379 -2382.
- Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus / D. J. Oh et al. // Korean J. Lab. Med. 2010. — Vol. 30, N 1. — P. 45 — 50.
- Evidence for persistence of human parvovirus B19 DNA in bone marrow / P. Cassinotti et al. // J. Med. Virol. 1997. — Vol. 53, N 3. — P. 229 — 232.
- Experimental parvoviral infection in humans / M. J. Anderson et al. // J. Infect. Dis. 1985. — Vol. 152, N 2. — P. 257 — 265.
- False-negative serology in patient with acute parvovirus B19 infection / S. Bredl et al. // J. Clin. Virol. 2011. — Vol. 51, N 2. — P. 115 — 120.
- Fattet, S. Persistent human parvovirus B19 infection in children under maintenance chemotherapy for acute lymphocytic leukemia / S. Fattet, P. Cassinotti, M. B. Popovic // J. Pediiat. Hematol. One. 2004. — Vol. 26, N 8. — P. 497 — 503.
- First continuous propagation of B19 parvovirus in a cell line / S. Shimomura et al. // Blood. -1992. -Vol. 79, N 1.-P. 18 24.
- Genetic diversity of human parvovirus B19: sequence analysis of the VP1/VP2 gene from multiple isolates / D. D. Erdman et al. // J. Gen. Virol. 1996. — Vol. 77, N 11.-P. 2767−2774.
- Genetic diversity within human erythroviruses: identification of three genotypes / A. Servant et al. // J. Virol. 2002. — Vol. 76, N 18. — P. 9124 — 9134.
- Genetic variants of human parvovirus B19 in South Africa: cocirculation of three genotypes and indentification of a novel subtype of genotype 1 / C. Corcoran et al. // J. Clin. Microbiol. 2010. — Vol. 48, N 1. — P. 137 — 142.
- Genotyping of human parvovirus B19 among Brazilian patients with hemoglobinopathies / S. N. Slavov et al. // Can. J. Microbiol. 2012. — Vol. 58, N 2.-P. 200−205.
- Groeneveld, K. Blood products and parvovirus B19 / K. Groeneveld, J. van der Noordaa // Neth. J. Med.-2003.-Vol. 61, N5.-P. 154- 156.
- Heat sensitivity of human parvovirus B19 / M. Yunoki et al. // Vox Sang. -2003. Vol. 84, N 3. — P. 164 — 169.
- Heegaard, E. D. Human parvovirus B19 / E. D. Heegaard, K. E. Brown // Clin. Microbiol. Rev. 2002. — Vol. 15, N 3. — P. 485 — 505.
- Heegaard, E. D. Parvovirus B19 infection associated with encephalitis in a patient suffering from malignant lymphoma / E. D. Heegaard, N. A. Peterslund, A. Hornsleth // Scand. J. Infect. Dis. 1995. — Vol. 27, N 6. — P. 631 — 633.
- High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy / T. Schenk et al. // J. Clin. Microbiol. 2009. — Vol. 47, N 1. — P. 106 — 110.
- Higher prevalence of parvovirus B19 in Belgian as compared to Tunisian blood donors: differential implications for prevention of transfusional transmission / M. Letaief et al. // Transfus. Sci. 1997. — Vol. 18, N 4. — P. 523 — 530.
- High-sensitivity PCR detection of parvovirus B19 in plasma / P. Daly et al. // J. Clin. Microbiol. 2002. — Vol. 40, N 6. — P. 1958 — 1962.
- High-titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation / T. Weimer et al. // Transfusion. 2001. — Vol. 41, N 12.-P. 1500- 1504.
- Horowitz, B. Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin / B. Horowitz, M. Busch // Transfusion. 2008. — Vol. 48, N 8. — P. 1739 — 1753.
- Human parvovirus arthropathy / D. G. White et al. // Lancet. 1985. — Vol. 1, N8426.-P. 419−421.
- Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction / K. Zakrzewska et al. // Br. J. Haematol. -1992. Vol. 81, N 3. — P. 407 — 412.
- Human parvovirus В19 infection and autoimmunity / C. Lunardi et al. // Autoimmun. Rev. 2008. — Vol .8, N 2. — P. 116 — 120.
- Human parvovirus В19 infection in hemophiliacs first infused two high-purity, virally attenuated factor VIII concentrates / A. Azzi et al. // Am. J. Hematol. 1992. -Vol. 39, N3.-P. 228−230.
- Human parvovirus В19 specific IgG, IgA, and IgM antibodies and DNA in serum specimens from persons with erythema infectiosum / D. D. Erdman et al. // J. Med. Virol. 1991. — Vol.35, N 2. — P. 3523 — 3524.
- Human parvovirus В19 surveillance in patients with rash and fever from Belarus / M. A. Yermalovich et al. // J. Med. Virol. 2012. — Vol. 84, N 6. — P. 973 -978.
- Human parvovirus В19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions / S. N. Slavov et al. // FEMS Immunol. Med. Microbiol. 2011. — Vol. 62, N 3. — P. 247 — 262.
- Human parvovirus В19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients / J. Jordan et al. // Vox Sang. 1998. -Vol. 75, N2.-P. 97- 102.
- Human parvovirus infection in hemophiliacs first infused with clotting factor concentrates / O. Bartolomei Corci et al. // J. Med. Virol. 1988. — Vol. 25, N 2. -P. 165- 170.
- Human parvovirus-associated arthritis: a clinical and laboratory description / D. M. Reid et al. // Lancet. 1985. — Vol. 1, N 8426. — P. 422 — 425
- Identification and characterization of a second novel human erythrovirus variant, A6 / Q. T. Nguyen et al. // Virology. 2002. — V. 301, N 2 — P. 374 — 380.
- Identification and characterization of persistent human erythrovirus infection in blood donor samples / D. Candotti et al. // J. Virol. 2004. — Vol. 78, N 22. — P. 12 169- 12 178.
- Identification and genetic diversity of two human parvovirus В19 genotype 3 subtypes / A. Parsyan et al. // J. Gen. Virol. 2007. — Vol. 88, N 2. — P. 428 — 431.
- Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments / S. F. Cotmore et al. // J. Virol. 1986. — Vol. 60, N 2. -P. 548−557.
- Immune response to B19 parvovirus and an antibody defect in persistent viral infection / G. J. Kurtzman et al. // J. Clin. Investig. 1989. — Vol. 84, N 4. — P. 1114−1123.
- In vitro propagation of parvovirus B19 in primary foetal liver culture / K. E. Brown et al. // J. Gen. Virol. 1991. — Vol. 72, N 3. — P. 741 — 745.
- Inactivation and neutralization of parvovirus B19 genotype 3 / J. Blumel et al. // Transfusion. 2012. — Vol. 52, N 7. — P. 1490 — 1497.
- Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparation / M. Yunoki et al. // Br. J. Haematol. 2005. — Vol. 128, N 3. — P. 401 — 404.
- Inactivation of parvovirus B19 during pasteurization of human serum albumin / J. Blumel et al. // Transfusion. 2002. — Vol.42, N 8. — P. 1011−1018.
- Incidence of human parvovirus B19 DNA detection in blood donors / Y. Yoto et al. // Br. J. Haematol. 1995. — Vol. 91, N 4. — P. 1017 — 1018.
- Induction of antiphospholipid antibodies and antiphospholipid syndrome-like in naive mice with antibody against human parvovirus B19 VP1 unique region protein / B. S. Tzang et al. // Clin. Chim. Acta. 2007. — Vol. 382, N 1 — 2. — P. 31 -36.
- Infection of the erythroid cell line KU812Ep6 with human parvovirus B19 and application to titration of B19 infectivity / E. Miyagawa et al. // J. Virol. Methods. -1999. Vol. 83, N 1 — 2. — P. 45 — 54.
- Intrauterine parvovirus infection associated with hydrops fetalis / T. A. Brown et al. // Lancet. 1984. — Vol. 324, N 8410. — P. 1033 — 1034
- Investigation of the prevalence of human parvovirus B19 in Korean plasmapheresis donors / D. J. Oh et al. // Korean J. Lab. Med. 2010. — Vol. 30, N l.-P. 58−64.
- Joseph, P. R. Fifth disease: the frequency of joint involvement in adults / P.R. Joseph//N. Y. State J. Med. 1986.-Vol. 86, N l.-P. 560−563
- Kaufmann, B. The structure of human parvovirus В19 / В. Kaufmann, A. A. Simpson, M. G. Rossmann // PNAS. 2004. — Vol. 101, N 32. -P. 11 628 — 11 633.
- Kishore, J. Standardization of B19 IgG ELISA to study the seroepidemiology of parvovirus В19 in North Indian voluntary blood donors / J. Kishore, M. Srivastava, N. Choudhary // Asian J. Transfus. Sci. 2010. — Vol. 4, N 2. — P. 86 — 90
- Koduri, P. R. Novel cytomorphology of the giant proerythroblasts of parvovirus B19 infection / P. R. Koduri // Am. J. Hematol. 1998. — Vol. 58, N 2. -P. 95 — 99.
- Koenigbauer, U. F. Clinical illness due to parvovirus В19 infection after infusion of solvent/detergent-treated pooled plasma / U. F. Koenigbauer, T. Eastlund, J. W. Day // Transfusion. 2000. — Vol. 40, N 10 — P. 1203 — 1206.
- Koppelman, M. H. Real-time polymerase chain reaction detection of parvovirus В19 DNA in blood donations using a commercial and an in-house assay / M. H. Koppelman, P. van Swieten, H. T. Cuijpers // Transfusion. 2011. — Vol. 51, N6.-P. 1346- 1354.
- Ku80 autoantigen as a cellular coreceptor for human parvovirus В19 infection / Y. Munakata et al. // Blood. 2005. — Vol. 106, N 10. — P. 3449 — 3456.
- Laboratory infection with human parvovirus В19 / H. Shiraishi et al. // J. Infect. 1991. — Vol. 22, N 3. — P. 308 — 310.
- Laboratory infection with parvovirus B19 / B. J. Cohen et al. // J. Clin. Pathol. 1988. — Vol. 41, N 9. — P. 1027 — 1028.
- Large-scale screening for human parvovirus В19 DNA by PCR: application to the quality control of plasma for fractionation / J. T. Aubin et al. // Vox Sang. -2000.-Vol. 78, N l.-P. 7- 12
- Laub, R. Parvoviruses and blood products / R. Laub, P. Strengers // Pathol. Biol. 2002. — Vol. 50, N 5. — P. 339 — 348.
- Lefrere, J. J. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates / J. J. Lefrere, M. Mariotti, M. Thauvin // Lancet. 1994. -Vol.343, N8891.-P. 211−212.
- Lefrere, J. J. Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products / J. J. Lefrere, M. Mariotti // Cell. Mol. Biol. 1995. — Vol. 41, N 7. — P. 985 — 988.
- Lehman, H. W. Parvovirus B19 infection and autoimmune disease / H. W. Lehman, P. von Landerberg, S. Modrow // Autoimmun. Rev. 2003. — Vol.2, N4-P. 218−223.
- Matejtschuk, P. Production of human albumin solution: a continually developing colloid / P. Matejtschuk, C. H. Dash, E. W. Gascoigne // Br. J. Anaesth. -2000. Vol. 85, N 6. — P. 887 — 895.
- MEGA 5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods / K. Tamura et al. // Molecular Biology and Evolution. 2011. — Vol. 28, N 10. — P. 2731 — 2739.
- Molecular characterization of human erythrovirus B19 strains obtained from patients with several clinical presentations in the Amazon region of Brazil / R. B. Freitas et al. // J. Clin. Virol. 2008. — Vol. 43, N 1. — P. 60 — 65.
- Molecular characterization of human parvovirus B19 genotypes 2 and 3 / Z. Chen et al. // J. Virol. 2009. — Vol. 394, N 2. — P. 276 — 285.
- Molecular mechanism underlying B19 virus inactivation to other parvoviruses / B. Mani et al. // Transfusion. 2007. — Vol. 47, N 10. — P. 1765 — 1774.
- Molecular testing for detection of in vitro infectivity of plasma pools contaminated with B19 virus / F. Bonvicini et al. // J. Med. Virol. 2004. — Vol. 74, N2.-P. 272−276.
- Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins / J. Modrof et al. // Transfusion. 2008. — Vol. 48, N 1. — P. 178 — 186.
- Neutralizing linear epitopes of B19 parvovirus cluster in the unique and VP1-VP2 junction regions / T. Saikawa et al. // J. Virol. 1993. — Vol. 67, N 7 — P. 3004- 3009.
- Novel human erythrovirus associated with transient aplastic anemia / Q. T. Nguyen et al. // J. Clin. Microbiol. 1999. — Vol. 37, N 8. — P. 2483 — 2487.
- Novel transcription map for the B19 (human) pathogenic parvovirus / K. Ozawa et al. // J. Virol. 1987. — Vol. 61, N 8. — P. 2395 — 2406.
- NS1 protein of parvovirus B19 interacts directly with DNA sequences of the p6 promoter and with the cellular transcription factors Spl/Sp3 / U. Raab et al. // Virology. 2002. — Vol. 293, N 1. — P. 86 — 93.
- Nucleotide sequence and genome organization of human parvovirus B19 isolate from the serum of a child during aplastic crisis / R. O. Shade et al. // J. Virol.- 1986. Vol. 58, N 3. — P. 921 — 936.
- Ozawa, K. Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures / K. Ozawa, N. Young // J. Virol. 1987. — Vol. 61, N 7. — P. 2627 — 2630.
- Ozawa, K. Productive infection by B19 parvovirus of human erythroid bone marrow cells in vitro / K. Ozawa, G. Kurtzman, N. Young // Blood. 1987. — Vol. 70, N2.-P. 384−391.
- Parsyan, A. Human erythrovirus B19 and blood transfusion an update / A. Parsyan, D. Candotti // Transfus. Med. — 2007. — Vol. 17, N 4. — P. 263 — 279.
- Parvovirus B19 among blood donors from three hospitals in Santiago, Chile / J. Levican et al. // Rev. Med. Chil. 2011. — Vol. 139, N 2. — 143 — 149.
- Parvovirus B19 DNA in Factor VIII concentrates: effects of manufacturing procedures and B19 screening by nucleic acid testing / Y. Geng et al. // Transfusion.- 2007. Vol. 47, N 5. — P. 883 — 889.
- Parvovirus B19 DNA in plasma pools and plasma derivatives /1. Schmidt et al. // Vox Sang. 2001. — Vol. 81, N 4. — P. 228 — 235.
- Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products / A. M. Eis-Hubinger et al. // Thromb. Haemost. 1996. — Vol. 76, N 6.-P. 1120.
- Parvovirus B19 genotypes 1 and 2 detection with real-time polymerase chain reaction assays / M. H. Koppelman et al. // Vox Sang. 2007. — Vol. 93, N 3. — P. 208−215.
- Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection / J. Mossong et al. // Epidemiol. Infect. -2008. Vol. 136, N 8. — P. 1059 — 1068.
- Parvovirus B19 infection transmitted by transfusion of red blood cells confirmed by molecular analysis of linked donor and recipient samples / M. Y. Yu et al. // Transfusion. 2010. — Vol. 50, N 8. — P. 1712 — 1721.
- Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis / B. D. Poole et al. // Int. J. Med. Sei. 2011. — Vol. 8, N 2. — P. 88−96.
- Parvovirus B19 transmission by a heat-treated clotting factor concentrates / J. Blumel et al. // Transfusion. 2002. — Vol. 42, N 11 — P. 1473 — 1481.
- Parvovirus B19 transmission by a high-purityfactor VIII concentrate / C. G. Wu et al. // Transfusion. 2005. — Vol. 45, N 6 — P. 1003 — 1010.
- Parvovirus B19: implications for transfusion medicine. Summary of a workshop / K. E. Brown et al. // Transfusion. 2001. — Vol. 41, N 1. — P. 130 -135.
- Parvovirus B19-Revised / J. Blumel et al. // Transfus. Med. Hemother. -2010. Vol. 37, N 6. — P. 339 — 350.
- Parvovirus-like particles in human sera / Y. E. Cossart et al. // Lancet. -1975.-Vol. 1, N 7898. P. 72−73.
- Peptides derived from the unique region of В19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits / S. Anderson et al. // Virology. -1995. Vol. 206, N 1. — P. 626 — 632.
- Persistent В19 in immunocompetent individuals: implications for transfusion safety / J. J. Lefrere et al. // Blood. 2005. — Vol. 106, N 8. — P. 2890 — 2895.
- Persistent infection by human parvovirus В19 in qualified blood donors / H. Matsukura et al. // Transfusion. 2008. — Vol. 48, N 5. — P. 1036 — 1037.
- Persistent parvovirus infection / S. Kerr et al. // Lancet. 1995. — Vol. 345, N 8957.-P. 1118.
- Phylogenetic analysis of human parvovirus В19, indicating two subgroups of genotype 1 in Vietnamese patients / N. L. Toan et al. // J. Gen. Virol. 2006. — Vol. 87, N 10.-P. 2941 -2949.
- Prevalence and quantitation of parvovirus В19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay / S. H. Kleiman et al. // Transfusion. 2007. — Vol. 47, N 10. — P. 1745 — 1750.
- Prevalence of human erythrovirus В19 DNA in healthy Belgian blood donors and correlation with specific antibodies against structural and non-structural viral proteins /1. Thomas et al. // Vox Sang. 2003. — Vol. 84, N 4. — P. 300 — 307.
- Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates / S. Modrow et al. // Vox Sang.-2011.-Vol. 100, N4.-P. 351 -358.
- Prevalence of parvovirus B19 and hepatitis A virus in Portuguese blood donors /1. Henriques et al. // Transfus. Apher. Sci. 2005. — Vol. 33, N 3. — P. 305 — 309.
- Prevalence of parvovirus В19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals / E. D. Heegaard et al. // J. Clin. Microbiol. 2002. — Vol. 40, N 3. — P. 933 — 936.
- Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination / F. Bonvicini et al. // Clin. Lab. -2006. Vol. 52, N 5 — 6. — P. 263 — 268
- Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy / G. J. Kurtzman et al. // N. Engl. J. Med. 1989. — Vol. 321, N 8. — P. 519 — 523.
- Purification and characterization of the major nonstructural protein (NS-1) of Aleutian mink disease parvovirus / J. Christensen et al. // J. Virol. 1995. — Vol. 69, N3.-P. 1802- 1809.
- Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay / J. R. Bostic et al. // J. Infect. Dis. 1999. — Vol. 179, N 3. — P. 619 — 626.
- Quantitative real-time detection of parvovirus B19 DNA in plasma / M. H. Koppelman et al. // Transfusion. 2004. -Vol. 44, N 1. — P. 97 — 103.
- Rapid sequence change and geographical spread of human parvovirus B19: comparison of B19 virus evolution in acute and persistent infections / P. Norja et al. // J. Virol. 2008. — Vol. 82, N 13. — P. 6427 — 6433.
- Reactivity of genotype-specific recombinant proteins of human erythrovirus B19 with plasmas from areas where genotype 1 or 3 is endemic / A. Parsyan et al. // J. Clin. Microbiol. 2006. — Vol. 44, N 4. — P. 1367 — 1375.
- Recipients potentially infected with parvovirus B19 by red blood cell products /M. K. Hourfar etal.//Transfusion.-2011.-Vol. 51, N l.-P. 129- 136.
- Regulation of human B19 parvovirus promoter expression by hGABP (E4TF1) transcription factor /1. Vassias et al. // J. Biol. Chem. 1998. — Vol. 273, N 14. — P. 8287−8293.
- Removal of parvovirus B19 from hemoglobin solution by nanofiltration / K. Abe et al. // Artif. Cells Blood Substit. Immobil. Biotechnol. 2000. — Vol. 28, N 5. -P. 375 -383.
- Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives / T. R. Kreil et al. // Transfusion. -2006.-Vol. 46, N7.-P. 1143−1151.
- Removal of small non-enveloped viruses by nanofiltration / T. Yokoyama et al. // Vox Sang. 2004. — Vol. 86, N 4. — P. 225 — 229.
- Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen) / K. E. Brown et al. // N. Engl. J. Med. 1994. — Vol. 330, N 17.-P. 1192- 1196.
- Rollag, H. Viral safety of blood derivatives by immune neutralization / H. Rollag, B. G. Solheim, J. L. Svennevig // Vox Sang. 1998. — Vol. 74, N 1. — P. 213 -217.
- Safety of blood products and B19 parvovirus / J. J. Lefrere et al. // Transfus. Clin. Biol. 2006. — Vol. 13, N 4. — P. 235 — 241.
- Schwarz, T. F. Comparison of seven commercial tests for the detection of parvovirus B19-specific IgM / T. F. Schwarz, G. Jager, S. Gilch // Zentralbl. Bakteriol. 1997. — Vol. 285, N 4. — P. 525 — 530.
- Screening of blood donors for human parvovirus B19 and characterization of the results / C. Wakamatsu et al. // Vox Sang. 1999. — Vol. 76, N 1. — P. 14 — 21.
- Self-assembled B19 parvovirus capsids, produced in a baculovirus system, are antigenically and immunogenically similar to native virions / S. Kajigaya et al. // PNAS.- 1991.-Vol. 88, N 11.-P. 4646−4650.
- Sequence variability among different parvovirus B19 isolates / A. Hemauer et al. // J. Gen. Virol. 1996. — V. 77, N 8. — P. 1781 — 1785.
- Sequence variability of human erythrovirus present in bone marrow of Brazilian patients with various parvovirus B19-related hematological symptoms / S. Sanabani et al. // J. Clin. Microbiol. 2006. — Vol. 44, N 2. — P. 604 — 606.
- Seroprevalence of parvovirus B19 IgG among blood donors in Aden, Yemen and Alexandria, Egypt / D. A. Al-Danani et al. // J. Chin. Clin. Medicine. 2008. -Vol. 3, N3.-P. 173- 176.
- Seroprevalence of parvovirus B19 in the German population / C. Rohrer et al. //Epidemiol. Infect. 2008. — Vol. 136, N11.-P. 1564- 1575.
- Shier, M. K. Human parvovirus B19 in Saudi blood donors / M. K. Shier, M. Badr // Egypt. J. Med. Microbiol. 2005. — Vol. 14, N 2. — P. 347 — 353.
- Simultaneous persistence of multiple genome variants of human parvovirus B19 / B. Schneider et al. // J. Gen. Virol. 2008. — Vol. 89, N 1. — P. 164 — 176.
- Structure and mapping of the DNA of human parvovirus B19 / J. Mori et al. // J. Gen. Virol. 1987. — Vol. 68, N 11. — P. 2797 — 2806.
- Successful replication of parvovirus B19 in the human megakaryocyte leukemia cell line MB-02 / N. C. Munshi et al. // J. Virol. 1993. — Vol. 67, N 1. -P. 562 — 566.
- Sun, I. Acute fulminant hepatitis with bone marrow failure in an adult due to parvovirus B19 infection /1. Sun, J. C. Zhang // Hepatology. 2012. — Vol. 55, N 1. -P. 329−330.
- Susceptibility of human erythropoietic cells to B19 parvovirus in vitro increases with differentiation / T. Takahashi et al. // Blood. 1990. — Vol. 75, N 3. -P. 603−610.
- Symptomatic parvovirus В19 infection caused by blood component transfusion / M. Satake et al. // Transfusion. 2011. — Vol. 51, N 9. — P. 1887 — 1895.
- The association of VP1 unique region protein in acute parvovirus В19 infection and anti-phospholipid antibody production / B. S. Tzang et al. // Clin. Chim. Acta. -2007. Vol. 378, N 1 — 2. — P. 59 — 65.
- The genome of human parvovirus В19 can replicate in nonpermissive cells with the help of adenovirus genes and produces infectious virus / W. Guan et al. // J. Virol. -2009. Vol. 83, N 18.-P. 9541 -9553.
- The globoside receptor triggers structural changes in the В19 virus capsid that facilitate virus internalization / C. Bonsch et al. // J. Virol. 2010. — Vol. 84, N 22. -P. 11 737- 11 746.
- The prevalence of human parvovirus В19 DNA and antibodies in blood donors from four Chinese blood centers / L. Ke et al. // Transfusion. 2011. — Vol. 51, N 9. -P. 1909- 1918.
- The small 11 kDa nonstructural protein of human parvovirus B19 plays a key role in inducing apoptosis during infection of primary erythroid progenitor cells / A. Y, Chen et al. // Blood. 2010. — Vol. 115, N 5. — P. 1070 — 1080.
- The structure of human parvovirus В19 at 8 A resolution / M. Agbandji et al. //Virology. 1994.-Vol. 203, N 1.-P. 106−115.
- The VP 1-unique region of parvovirus В19: amino acid variability and antigenic stability / S. Dorsch et al. // J. Gen. Virol. 2001. — Vol. 82, N 1. — P. 191 — 199.
- Transfusion-transmitted human parvovirus В19 infection in a thalassemic patient / A. Zanella et al. // Transfusion. 1995. — Vol. 35, N 9. — P. 769 — 772.
- Transmission of human parvovirus В19 by plasma derived factor VIII concentrates / Y. Laurian et al. // Nouv. Rev. Fr. Hematol. 1994. — Vol. 36, N 6.1. P. 449−453.
- Transmission of parvovirus В19 by coagulation factor concentrates exposed to 100 degrees С heat after lyophilization / E. Santagostino et al. // Transfusion. -1997. Vol. 37, N 5. — P. 517 — 522.
- Transmission of serum parvovirus-like virus by clotting-factor concentrates / P. P. Mortimer et al. // Lancet. 1983. — Vol. 2, N 8348. — P. 482 — 484.
- Variability of parvovirus В19 genotype 2 in plasma products with different compositions in the inactivation sensitivity by liquid-heating / M. Tsujikawa et al. // Vox Sang. 2012. — Vol. 102, N 2. — P. 93 — 99.
- Variability of parvovirus B19 to inactivation by liquid heating in plasma products / S. Hattori et al. // Vox Sang. 2007. — Vol. 92, N 2. — P. 121 — 124.
- Viral safety of Nanogam, a new 15 nm-flltred liquid immunoglobulin product / F. G. Terpstra et al. // Vox Sang. 2006. — Vol. 90, N 1. — P. 21 — 32.
- Viral safety of solvent/detergent-treated plasma / B. G. Solheim et al. // Transfusion. 2000. — Vol. 40, N 1. — P. 84 — 90.
- Yee, Т. T. Life-threatening human parvovirus В19 infection in immunocompetent haemophilia / Т. T. Yee, C. A. Lee, K. J. Pasi // Lancet. 1995. -Vol. 345, N 8952. — P.794 — 795.
- Young, N. S. Parvovirus В19 / N. S. Young, К. E. Brown // N. Eng. J. Med. -2004. Vol. 350, N 6. — P. 586 — 597.
- Zaaijer, H. L., Parvovirus B19 viremia in Dutch blood donors / H. L. Zaaijer, M. H. G. M. Koppelman, C. P. Farrington // Epidemiol. Infect. 2004. — Vol. 132, N 6.-P. 1161 — 1166.
- European Pharmacopoeia Electronic resource. 7 ed. — Электрон, дан. -Режим доступа: //http://www.edqm.eu/en/European-Pharmacopoeia-1401.html
- OB 19%20 White%20Paper.pdf
- International Committee on Taxonomy of Viruses (ICTV) Electronic resource. 2011. — Электрон, дан. — Режим доступа: // http://www.ictvonline.org